VBC106 / VelaVigo - LARVOL DELTA

First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=260 | Not yet recruiting | Sponsor: VelaVigo Bio Inc

First-in-human • New P1/2 trial • Oncology • Solid Tumor